Neurology Archives - Page 8 of 10

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations

Authors: J F Logman, B M Heeg, J Herlitz, B A van Hout Published: Applied Health Economics and Health Policy, 2010 View publication Background Antiplatelet therapy plays a central role in the...

Modelling the treated course of schizophrenia: development of a discrete event simulation model

Authors: B Heeg, E Buskens, M Knapp, G van Aalst, PJ Dries, L de Haan, BA van Hout. Published: PharmacoEconomics, 2010 View publication Abstract In schizophrenia, modelling techniques may be needed to...

Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model

Authors: M F Botteman, R J Ozminkowski, S Wang, C L Pashos, K Schaefer, D J Foley Published: CNS Drugs, 2010 View publication Objective Although the clinical benefits of pharmacological treatments for...

Prevalence and incidence of severe sepsis in Dutch intensive care units

Authors: A van Gestel, J Bakker, CP Veraart, BA van Hout. Published: Critical Care, 2010 View publication Objective Severe sepsis is a dreaded consequence of infection and necessitates intensive care treatment. Severe...

A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

Authors: K T Carpiuc, J M Stephens, M F Botteman, W Feng, J W Hay Published: Expert Opinion on Pharmacotherapy, 2010 View publication Abstract Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is...

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

Authors: B M Heeg, J Antunes, M L Figueira, J M Jara, J Marques Teixeira, A P Palha, A Vaz Serra, E Buskens, S Caleo, C Gouveia-Pinto, B A Van Hout. Published:...

A pharmacoeconomic analysis of compliance gains on antipsychotic medications

Authors: J Damen, P O Thuresson, B Heeg, M Lothgren Published: Applied Health Economics and Health Policy, 2010 View publication Background Compliance among patients with schizophrenia is typically poor. Consequently, treatments that...

The cost-effectiveness of atypicals in the UK

Authors: B Heeg, E Buskens, M Botteman, S Caleo, M Ingham, J Damen, F de Charro, B van Hout Published: Value Health, 2010 View publication Background In 2002, the National Institute for...

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

Authors: M Treur, B Heeg, H J Möller, A Schmeding, B van Hout Published: BMC Health Services Research, 2010 View publication Background As schizophrenia patients are typically suspicious of, or are hostile...

News